A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Administration of Single and Multiple Ascending Doses for 13 Days in Healthy Male and Female Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2010
At a glance
- Drugs AZD 9164 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Dec 2010 Planned end date changed from Jul 2010 to Jun 2010 as reported by ClinicalTrials.gov.
- 17 Nov 2010 Actual initiation date changed from Apr 2010 to Mar 2010 as reported by ClinicalTrials.gov.
- 29 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.